Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned wit
It's a case of so far, so good for BlueRock Therapeutics' first clinical trial of Parkinson's disease therapy bemdaneprocel, with no major safety issues reported after a y
Aspen Neuroscience is adding a digital dimension to a study of its experimental cell therapy for Parkinson's disease, with the help of tech companies Emerald Innovations a
Cellares has just closed a major $255 million third-round financing that will be used to complete a highly automated facility in New Jersey for the production of cell ther
Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.
